Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes. Sogorb-Esteve, A., Weiner, S., Simrén, J., Swift, I. J., Bocchetta, M., Todd, E. G., Cash, D. M., Bouzigues, A., Russell, L. L., Foster, P. H., Ferry-Bolder, E., van Swieten, J. C., Jiskoot, L. C., Seelaar, H., Sanchez-Valle, R., Laforce, R., Graff, C., Galimberti, D., Vandenberghe, R., de Mendonça, A., Tiraboschi, P., Santana, I., Gerhard, A., Levin, J., Sorbi, S., Otto, M., Pasquier, F., Ducharme, S., Butler, C. R., Ber, I. L., Finger, E., Tartaglia, M. C., Masellis, M., Rowe, J. B., Synofzik, M., Moreno, F., Borroni, B., GENFI, Blennow, K., Zetterberg, H., Rohrer, J. D., Gobom, J., Thomas, D. L., Cope, T., Rittman, T., Benussi, A., Premi, E., Gasparotti, R., Archetti, S., Gazzina, S., Cantoni, V., Arighi, A., Fenoglio, C., Scarpini, E., Fumagalli, G., Borracci, V., Rossi, G., Giaccone, G., Fede, G. D., Caroppo, P., Tiraboschi, P., Prioni, S., Radaaelli, V., Tang-Wai, D., Rogaeva, E., Castelo-Branco, M., Freedman, M., Keren, R., Black, S., Mitchell, S., Shoesmith, C., Bartha, R., Rademakers, R., Poos, J., Papma, J. M., Giannini, L., van Minkelen, R., Pijnenburg, Y., Nacmias, B., Ferrari, C., Polito, C., Lombardi, G., Bessi, V., Veldsman, M., Andersson, C., Thonberg, H., Öijerstedt, L., Jelic, V., Thompson, P., Langheinrich, T., Llado, A., Antonell, A., Olives, J., Balasa, M., Bargalló, N., Borrego-Écija, S., Verdelho, A., Maruta, C., Ferreira, C. B., Miltenberger, G., do Couto, F. S., Gabilondo, A., Villanua, J., Cañada, M., Tainta, M., Zulaica, M., Barandiaran, M., Alves, P., Bender, B., Wilke, C., Graf, L., Vogels, A., Vandenbulcke, M., van Damme, P., Buffaerts, R., Poesen, K., Rosa-Neto, P., Gauthier, S., Camuzat, A., Brice, A., Bertrand, A., Funkiewiez, A., Rinaldi, D., Saracino, D., Colliot, O., Sayah, S., Prix, C., Wlasich, E., Wagemann, O., Loosli, S., Schönecker, S., Hoegen, T., Lombardi, J., Anderl-Straub, S., Rollin, A., Kuchcinski, G., Bertoux, M., Lebouvier, T., Deramecourt, V., Santiago, B., Duro, D., Leitão, M. J., Almeida, M. R., Tábuas-Pereira, M., & Afonso, S. Science Translational Medicine, 2, 2025. Author list abbreviated in original export; additional authors not provided. INTERACTIONS team affiliation requires confirmation.
Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes [link]Paper  doi  abstract   bibtex   

We used an untargeted mass spectrometric approach, tandem mass tag proteomics, for the identification of proteomic signatures in genetic frontotemporal dementia (FTD). A total of 238 cerebrospinal fluid (CSF) samples from the Genetic FTD Initiative were analyzed, including samples from 107 presymptomatic (44 C9orf72 , 38 GRN , and 25 MAPT ) and 55 symptomatic (27 C9orf72 , 17 GRN , and 11 MAPT ) mutation carriers as well as 76 mutation-negative controls (“noncarriers”). We found shared and distinct proteomic alterations in each genetic form of FTD. Among the proteins significantly altered in symptomatic mutation carriers compared with noncarriers, we found that a set of proteins including neuronal pentraxin 2 and fatty acid binding protein 3 changed across all three genetic forms of FTD and patients with Alzheimer’s disease from previously published datasets. We observed differential changes in lysosomal proteins among symptomatic mutation carriers with marked abundance decreases in MAPT carriers but not other carriers. Further, we identified mutation-associated proteomic changes already evident in presymptomatic mutation carriers. Weighted gene coexpression network analysis combined with gene ontology annotation revealed clusters of proteins enriched in neurodegeneration and glial responses as well as synapse- or lysosome-related proteins indicating that these are the central biological processes affected in genetic FTD. These clusters correlated with measures of disease severity and were associated with cognitive decline. This study revealed distinct proteomic changes in the CSF of patients with genetic FTD, providing insights into the pathological processes involved in the disease. In addition, we identified proteins that warrant further exploration as diagnostic and prognostic biomarker candidates.

@article{Sogorb-Esteve2025,
   abstract = {<p> We used an untargeted mass spectrometric approach, tandem mass tag proteomics, for the identification of proteomic signatures in genetic frontotemporal dementia (FTD). A total of 238 cerebrospinal fluid (CSF) samples from the Genetic FTD Initiative were analyzed, including samples from 107 presymptomatic (44 <italic>C9orf72</italic> , 38 <italic>GRN</italic> , and 25 <italic>MAPT</italic> ) and 55 symptomatic (27 <italic>C9orf72</italic> , 17 <italic>GRN</italic> , and 11 <italic>MAPT</italic> ) mutation carriers as well as 76 mutation-negative controls (“noncarriers”). We found shared and distinct proteomic alterations in each genetic form of FTD. Among the proteins significantly altered in symptomatic mutation carriers compared with noncarriers, we found that a set of proteins including neuronal pentraxin 2 and fatty acid binding protein 3 changed across all three genetic forms of FTD and patients with Alzheimer’s disease from previously published datasets. We observed differential changes in lysosomal proteins among symptomatic mutation carriers with marked abundance decreases in <italic>MAPT</italic> carriers but not other carriers. Further, we identified mutation-associated proteomic changes already evident in presymptomatic mutation carriers. Weighted gene coexpression network analysis combined with gene ontology annotation revealed clusters of proteins enriched in neurodegeneration and glial responses as well as synapse- or lysosome-related proteins indicating that these are the central biological processes affected in genetic FTD. These clusters correlated with measures of disease severity and were associated with cognitive decline. This study revealed distinct proteomic changes in the CSF of patients with genetic FTD, providing insights into the pathological processes involved in the disease. In addition, we identified proteins that warrant further exploration as diagnostic and prognostic biomarker candidates. </p>},
   author = {Aitana Sogorb-Esteve and Sophia Weiner and Joel Simrén and Imogen J. Swift and Martina Bocchetta and Emily G. Todd and David M. Cash and Arabella Bouzigues and Lucy L. Russell and Phoebe H. Foster and Eve Ferry-Bolder and John C. van Swieten and Lize C. Jiskoot and Harro Seelaar and Raquel Sanchez-Valle and Robert Laforce and Caroline Graff and Daniela Galimberti and Rik Vandenberghe and Alexandre de Mendonça and Pietro Tiraboschi and Isabel Santana and Alexander Gerhard and Johannes Levin and Sandro Sorbi and Markus Otto and Florence Pasquier and Simon Ducharme and Chris R. Butler and Isabelle Le Ber and Elizabeth Finger and Maria Carmela Tartaglia and Mario Masellis and James B. Rowe and Matthis Synofzik and Fermin Moreno and Barbara Borroni and GENFI and Kaj Blennow and Henrik Zetterberg and Jonathan D. Rohrer and Johan Gobom and David L. Thomas and Thomas Cope and Timothy Rittman and Alberto Benussi and Enrico Premi and Roberto Gasparotti and Silvana Archetti and Stefano Gazzina and Valentina Cantoni and Andrea Arighi and Chiara Fenoglio and Elio Scarpini and Giorgio Fumagalli and Vittoria Borracci and Giacomina Rossi and Giorgio Giaccone and Giuseppe Di Fede and Paola Caroppo and Pietro Tiraboschi and Sara Prioni and Veronica Radaaelli and David Tang-Wai and Ekaterina Rogaeva and Michel Castelo-Branco and Morris Freedman and Ron Keren and Sandra Black and Sara Mitchell and Christen Shoesmith and Robart Bartha and Rosa Rademakers and Jackie Poos and Janne M. Papma and Lucia Giannini and Rick van Minkelen and Yolande Pijnenburg and Benedetta Nacmias and Camilla Ferrari and Cristina Polito and Gemma Lombardi and Valentina Bessi and Michele Veldsman and Christin Andersson and Hakan Thonberg and Linn Öijerstedt and Vesna Jelic and Paul Thompson and Tobias Langheinrich and Albert Llado and Anna Antonell and Jaume Olives and Mircea Balasa and Nuria Bargalló and Sergi Borrego-Écija and Ana Verdelho and Carolina Maruta and Catarina B. Ferreira and Gabriel Miltenberger and Frederico Simões do Couto and Alazne Gabilondo and Jorge Villanua and Marta Cañada and Mikel Tainta and Miren Zulaica and Myriam Barandiaran and Patricial Alves and Benjamin Bender and Carlo Wilke and Lisa Graf and Annick Vogels and Mathieu Vandenbulcke and Philip van Damme and Rose Buffaerts and Koen Poesen and Pedro Rosa-Neto and Serge Gauthier and Agnès Camuzat and Alexis Brice and Anne Bertrand and Aurélie Funkiewiez and Daisy Rinaldi and Dario Saracino and Olivier Colliot and Sabrina Sayah and Catharina Prix and Elisabeth Wlasich and Olivia Wagemann and Sandra Loosli and Sonja Schönecker and Tobias Hoegen and Jolina Lombardi and Sarah Anderl-Straub and Adeline Rollin and Gregory Kuchcinski and Maxime Bertoux and Thibaud Lebouvier and Vincent Deramecourt and Beatriz Santiago and Diana Duro and Maria João Leitão and Maria Rosario Almeida and Miguel Tábuas-Pereira and Sónia Afonso},
   doi = {10.1126/scitranslmed.adm9654},
   issn = {1946-6234},
   issue = {784},
   journal = {Science Translational Medicine},
   month = {2},
   note = {Author list abbreviated in original export; additional authors not provided.
INTERACTIONS team affiliation requires confirmation.},
   title = {Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes},
   volume = {17},
   url = {https://www.science.org/doi/10.1126/scitranslmed.adm9654},
   year = {2025}
}

Downloads: 0